Evidence map›Paper›PMID 37687169›Full record

ArticleMolecules (Basel, Switzerland)2023

Discovery of a Novel Ubenimex Derivative as a First-in-Class Dual CD13/Proteasome Inhibitor for the Treatment of Cancer.

Jian Zhang, Simin Sun, Jinyu Liu, Liang Zhang, Di Guo, Naixin Zhang, Jun Zhao, Dexin Kong, Tongqiang Xu, Xuejian Wang and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Antitumor effect of BC12-3 on multiple myeloma via proteasome inhibition.Medical oncology (Northwood, London, England) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Jian ZhangCollege of Pharmacy, Weifang Medical University, Weifang 261053, China.
Simin SunKey Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao 266003, China.
Jinyu LiuKey Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao 266003, China.
Liang ZhangKey Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao 266003, China.
Di GuoCollege of Pharmacy, Weifang Medical University, Weifang 261053, China.
Naixin ZhangTianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.
Jun ZhaoMarine Biomedical Research Institute of Qingdao, Qingdao 266071, China.
Dexin KongTianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.ORCID 0000-0002-8064-1435
Tongqiang XuMarine Biomedical Research Institute of Qingdao, Qingdao 266071, China.
Xuejian WangCollege of Pharmacy, Weifang Medical University, Weifang 261053, China.
Wenfang XuMarine Biomedical Research Institute of Qingdao, Qingdao 266071, China.
Xiaoyang LiKey Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao 266003, China.ORCID 0000-0003-3684-2106
Yuqi JiangKey Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao 266003, China.ORCID 0000-0002-6612-4888
Marine Biomedical Research Institute of Qingdao · CNOcean University of China · CNWeifang Medical University · CNQingdao National Laboratory for Marine Science and Technology · CNTianjin Medical University · CN

Funding

National Natural Science Foundation of China 81803368National Natural Science Foundation of China 82003584National Natural Science Foundation of China 82103983Natural Science Foundation of Shandong Province ZR2019QH015Natural Science Foundation of Shandong Province ZR2020QH343The Key research and development program of Shandong province 2020CXGC010503The Marine S&T Fund of Shandong Province for Pilot National Laboratory for Marine Science and Technology (Qingdao) 2018SDKJ0403The Taishan Scholars Program tsqn202211296
6 · The paper itself

Abstract

The CD13 inhibitor ubenimex is used as an adjuvant drug with chemotherapy for the treatment of cancer due to its function as an immunoenhancer, but it has limitations in its cytotoxic efficacy. The proteasome inhibitor ixazomib is a landmark drug in the treatment of multiple myeloma with a high anti-cancer activity. Herein, we conjugated the pharmacophore of ubenimex and the boric acid of ixazomib to obtain a dual CD13 and proteasome inhibitor

Indexed as

Multiple MyelomaProteasome InhibitorsAntiviral AgentsBoron CompoundsEnzyme TherapyGlycineHumansLeucineAntiviral AgentsBoron CompoundsGlycineixazomibLeucineProteasome Inhibitorsubenimexanti-canceranti-metastasisCD13 inhibitormultiple myelomaproteasome inhibitor

Identifiers

PMID37687169
PMCPMC10489073
OpenAlexW4386303351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.